SUTENT (SUNITINIB, SU11248) in Patients With Recurrent or Progressive Glioblastoma Multiforme An Academic Prospective Single-Arm Phase II Clinical Trial Including Translational Research Studies.
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 01 Jan 2014
At a glance
- Drugs Sunitinib (Primary)
- Indications Glioblastoma
- Focus Therapeutic Use
- 27 Aug 2010 Status changed from recruiting to active, no longer recruiting as reported by ClinicalTrials.gov.
- 27 Aug 2010 Planned end date changed from 1 Jun 2010 to 1 Jan 2011 as reported by ClinicalTrials.gov.
- 03 Feb 2009 Additional lead investigator identified as reported by ClinicalTrials.gov, last updated 3-2-2009.